-
ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers
Combination checkpoints, improved CAR T cells show promise.
-
ASCO 2016 Update: The Value of Combination Immunotherapy
Activating multiple immune pathways to improve patient outcomes.
-
ASCO 2016 Update: The Personal Side of Immunotherapy
To help more patients, treatments must get personal.
-
ASCO 2016: The Year of Immunotherapy
Chicago hosts top clinical cancer conference, immunotherapy shines.
-
The Evolution of Cancer Treatment: From Simplistic Strategies to Personalized Prescriptions
Immunotherapy, personalized medicine poised to revolutionize cancer treatment.
-
Immunotherapy in the Spotlight
Dateline NBC took a closer look at this revolution known as immunotherapy and plans to tap into…
-
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer
It becomes the first FDA-approved checkpoint blockade immunotherapy for bladder cancer.
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.
-
#AACR16 Update: Vice President Biden and the National Cancer Moonshot Initiative
VP Biden addresses AACR16 seeking suggestions and solutions.
